Drug Technology Targets Alzheimer’s Disease

Alzheimer’s disease is a devastating neurodegenerative disorder that is increasing at alarming rates around the world. The Alzheimer’s Association estimates that by 2050 nearly 12 million Americans and 45 million people worldwide will be afflicted with this chronic, debilitating condition.

A new weapon against Alzheimer’s disease has been invented at the George S. Wise Faculty of Life Sciences at Tel Aviv University in Israel. The novel pharmaceutical technology consists of drug candidates with a unique mechanism of action that targets the very early stages of Alzheimer’s disease.

This technology was developed from 2003 to 2007 by a research team led by professor Ehud Gazit, Ph.D. The project was part of a portfolio of technologies funded by an $8.5 million investment raised by Ramot at Tel Aviv University Ltd., the university’s technology transfer company. A group of U.S. investors provided the investment capital.

Tel Aviv University licensed the discovery to Merz Pharmaceuticals GmbH in 2007. Merz is one of the world’s leading pharmaceutical companies in Alzheimer’s disease research and development.

To see available technologies from research institutions, click here to visit the AUTM Innovation Marketplace.